Overview

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects

Status:
COMPLETED
Trial end date:
2023-11-16
Target enrollment:
Participant gender:
Summary
Study Design : A randomized, open-label, four-sequence, four-period, crossover, single dosing, phase 1 study
Phase:
PHASE1
Details
Lead Sponsor:
Bukwang Pharmaceutical
Collaborator:
Dyna Therapeutics
Treatments:
Abiraterone Acetate